Patent · US Active

PODXL in bladder cancer

US9354232B2 · kind B2 · utility

0Cited by
0References
21Claims
0Family size

Assignee

Inventor

Key dates

Filing dateDec 11, 2013
Grant dateMay 31, 2016
Priority date
Expiry dateDec 11, 2033

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

There is provided a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the second group is worse than the prognosis of subjects of the first group, comprising the steps of: a) evaluating an amount of PODXL in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the first group.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.